Liver/Biliary Disorders

Top Story

Samsca effective in difficult-to-treat cirrhotic ascites

August 18, 2017

Samsca, also known as tolvaptan, was safe when combined with conventional diuretics and presented promising results in treating patients with difficult-to-treat cirrhotic ascites, according to results of a recent prospective study. Blood urea nitrogen was a favorable marker for selecting patients most likely to respond to treatment.

“The main differences between tolvaptan and conventional diuretics are that tolvaptan does not stimulate the sodium channel and increases free water excretion without affecting urinary sodium and potassium excretion,” Hideto Kawaratani, MD, PhD, from the Nara Medical University, Japan, and colleagues wrote. “This mechanism seems to reduce the occurrence of diuretic-induced electrolyte abnormalities or renal failure.”

Two liver cancer T-cell therapies receive orphan drug designation

August 17, 2017
The FDA recently granted two orphan drug designations to Lion TCR for T-cell therapy products for the treatment of hepatocellular carcinoma, according to a press…

Health Canada approves Vosevi for retreatment of chronic HCV

August 17, 2017
Health Canada approved Gilead’s Vosevi for treating patients with chronic hepatitis C with genotypes 1 through 6 previously treated with an NS5A…

Health Canada approves Maviret for pangenotypic chronic HCV

August 17, 2017
Health Canada approved AbbVie’s Maviret for treating adults with chronic hepatitis C for all genotypes, according to a press release. Maviret is designated for…
More Headlines »
CME

Real World Perspectives on HCV: Barriers, Debates, and New Models of Care in GI Practice

This activity is supported by an educational grant from Gilead.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Question 21: What is the Best Screening Test for Wilson's Disease?

From Curbside Consultation of the Liver: 49 Clinical Questions
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

Video
Meeting News

VIDEO: Public action required to improve NAFLD diagnostics, treatment

March 24, 2017
More »
Advertisement
Advertisement